Insider Trading Activity Syndax Pharmaceuticals Inc (NASDAQ:SNDX) – Insider Sold 5,000 shares of Stock

17

Insider Trading Activity For Syndax Pharmaceuticals Inc (NASDAQ:SNDX)

Peter Ordentlich , Insider of Syndax Pharmaceuticals Inc (NASDAQ:SNDX) reportedly Sold 5,000 shares of the company’s stock at an average price of 15 for a total transaction amount of $75,000.00 SEC Form

Insider Trading History For Syndax Pharmaceuticals Inc (NASDAQ:SNDX)

  • On 3/8/2016 Ivor Royston, Director, bought 150,000 with an average share price of $12.00 per share and the total transaction amounting to $1,800,000.00. View SEC Filing
  • On 5/17/2017 Peter Ordentlich, Insider, sold 5,000 with an average share price of $15.00 per share and the total transaction amounting to $75,000.00. View SEC Filing
  • Analyst Ratings For Syndax Pharmaceuticals Inc (NASDAQ:SNDX)
    These are 1 Sell Rating, 9 Buy Ratings .
    The current consensus rating for Syndax Pharmaceuticals Inc (NASDAQ:SNDX) is Buy (Score: 2.80) with a consensus target price of $26.17 , a potential (86.37% upside)

    Analyst Ratings History For Syndax Pharmaceuticals Inc (NASDAQ:SNDX)

      with a price target of $22.00 to $24.00

    • On 10/7/2016 Guggenheim Initiated Coverage of rating Buy with a price target of $29.00
    • On 11/9/2016 JMP Securities Reiterated Rating Buy
    • On 12/30/2016 BTIG Research Initiated Coverage of rating Buy with a price target of $25.00
    • On 3/1/2017 Nomura Initiated Coverage of rating Buy
    • On 3/1/2017 Instinet Initiated Coverage of rating Buy to Buy with a price target of $27.00
    • On 3/16/2017 FBR & Co Initiated Coverage of rating Outperform to Outperform with a price target of $27.00

    About Syndax Pharmaceuticals Inc (NASDAQ:SNDX)
    Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

    Recent Trading Activity for Syndax Pharmaceuticals Inc (NASDAQ:SNDX)
    Shares of Syndax Pharmaceuticals Inc closed the previous trading session at 14.21 up +0.17 1.21% with 899,503 shares trading hands.

    An ad to help with our costs